Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer

Inclusion Criteria:

* Male patients \>= 18 years old.
* Patients with histologically proven seminomatous or non-seminomatous germ cell cancer
* Disease progression during cisplatin-based chemotherapy or
* Disease progression or relapse after high-dose chemotherapy or
* Disease progression or relapse after at least 2 different cisplatin-based regimens and contraindications for high-dose chemotherapy.
* Patients must have received prior combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel (GOP). Prior treatment with a combination of two of these drugs is allowed in case of contraindications for GOP.
* Disease progression at study entry: progressive disease according to RECIST criteria in baseline examinations or tumor marker increase \> 25% within 4 weeks before study entry.
* ECOG performance status \<= 2.
* Life expectancy \>= 3 months.
* Adequate bone marrow function: absolute neutrophil count \>= 1.5 x 109/1, platelets \>= 75 x 109/1, hemoglobin \>= 9 g/dl.
* Adequate liver function: serum bilirubin: \<= 1.5x ULN, ALT and AST \<= 2.5x ULN. For patients with known liver metastases: AST and ALT \<= 5x ULN.
* Adequate renal function: serum creatinine \<= 2.0x ULN.
* Patients must be surgically sterile or must agree to use effective contraception during study treatment.
* Signed written informed consent.

Exclusion Criteria:

* Systemic antitumor treatment within 21 days before study entry.
* Simultaneous radiotherapy of the only target lesion(s).
* Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above
* Patients who have previously received mTOR inhibitors (sirolimus, temsirolimus, everolimus).
* Patients receiving chronic systemic treatment with corticosteroids (dose of \>= 20 mg/day methylprednisone equivalent) or another immunosuppressive agent.
* Patients with unstable angina pectoris, myocardial infarction \<= 6 months prior to first study treatment, congestive heart failure NYHA III-IV or serious uncontrolled cardiac arrhythmias.
* Patients with severely impaired lung function: spirometry or DLCO \< 50% of the normal predicted value.
* Uncontrolled diabetes: fasting serum glucose \> 2.0x ULN.
* Patients with an active or uncontrolled infection, incl. chronic Hepatitis B or C
* Patients who have a history of another primary malignancy and are off treatment for \<= 3 years, with the exception of non-melanoma skin cancer.
* Patients who have participated in another clinical trial within 30 days before study entry.
* Other serious medical conditions that could impair the ability of the patient to participate in the study.
* Patients unwilling or unable to comply with the protocol.